This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).
Patients aged 19 years or older.
Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction [STEMI] or non-ST-segment elevation myocardial infarction [NSTEMI]).
Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).
Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.
History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker [P-CAB] or proton pump inhibitor [PPI]).
Presence of active gastrointestinal bleeding.
Pregnant or breastfeeding women.
Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).
Parallel
Zastaprazan
DrugZastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.
Proton Pump Inhibitors (PPI)
DrugGuideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.
Net Adverse Clinical Events (NACE)
A composite of death from any causes, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3-5 bleeding.
Click on the lead sponsor to view all of their trials.
